Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ziprasidone Mesylate

FDA-approved product (powder, intramuscular), marketed as Geodon, Ziprasidone Hydrochloride, Ziprasidone Mesylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ziprasidone Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Bipolar disorder
  • Bipolar I disorder
  • Cardiac arrhythmia
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Ventricular tachycardia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ziprasidone Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ziprasidone Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

    NCT06482554 · start 2024-06

    Registered record
    Registry ID
    NCT06482554
    Conditions
    Apathy; Schizophrenia; Schizophrenia; Psychosis
    Interventions
    Lumateperone 42 mg; Risperidone 2 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-06
    Completion
    2026-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionApathy; Schizophrenia; Schizophrenia; Psychosis
    InterventionLumateperone 42 mg; Risperidone 2 mg
    PhasePhase 3
    Registry statusRecruiting

  • Maternal And Infant Antipsychotic Study

    NCT06049953 · start 2023-09-29

    Registered record
    Registry ID
    NCT06049953
    Conditions
    Antipsychotics; Pregnancy
    Interventions
    Antipsychotics; Non-antipsychotic medication; No Medication
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-09-29
    Completion
    2028-01-01
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntipsychotics; Pregnancy
    InterventionAntipsychotics; Non-antipsychotic medication; No Medication
    PhaseNot recorded
    Registry statusRecruiting

  • Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

    NCT03211897 · start 2017-06-15

    Registered record
    Registry ID
    NCT03211897
    Conditions
    Agitation,Psychomotor
    Interventions
    Haloperidol Injection; Ziprasidone Injection; OLANZapine Injection; Midazolam injection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-06-15
    Completion
    2017-10-01
    Enrolment
    737

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAgitation,Psychomotor
    InterventionHaloperidol Injection; Ziprasidone Injection; OLANZapine Injection; Midazolam injection
    PhaseNot recorded
    Registry statusCompleted

  • The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients

    NCT03007303 · start 2016-06

    Registered record
    Registry ID
    NCT03007303
    Conditions
    Schizophrenia; Micrognathia
    Interventions
    Atypical Antipsychotic; atypical antipsychotic combined with MECT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2020-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Micrognathia
    InterventionAtypical Antipsychotic; atypical antipsychotic combined with MECT
    PhaseNot recorded
    Registry statusUnknown

  • Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

    NCT02307396 · start 2015-02-01

    Registered record
    Registry ID
    NCT02307396
    Conditions
    Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    Interventions
    Olanzapine; Amisulpride; Risperidone; Haloperidol; Quetiapine; Perphenazine; Sulpiride; bromperidol; Zuclopenthixol; Thioridazine; Paliperidone; Ziprasidone; Benperidol; Fluspirilene; Pimozide; Perazine; Fluphenazine; Flupentixole; Sertindole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2016-06-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    InterventionOlanzapine; Amisulpride; Risperidone; Haloperidol +15 more
    PhasePhase 4
    Registry statusCompleted

  • Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

    NCT01893229 · start 2013-09

    Registered record
    Registry ID
    NCT01893229
    Conditions
    Bipolar Disorder
    Interventions
    Lithium; Valproate; Oxcarbazepine; Quetiapine; Olanzapine; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-09
    Completion
    2015-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionLithium; Valproate; Oxcarbazepine; Quetiapine +2 more
    PhasePhase 4
    Registry statusUnknown

  • 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

    NCT01844700 · start 2013-07

    Registered record
    Registry ID
    NCT01844700
    Conditions
    High Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
    Interventions
    Ziprasidone; aripiprazole, quetiapine, or risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2014-04
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
    InterventionZiprasidone; aripiprazole, quetiapine, or risperidone
    PhasePhase 4
    Registry statusTerminated

  • An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

    NCT01498770 · start 2013-04-01

    Registered record
    Registry ID
    NCT01498770
    Conditions
    Bipolar Disorder
    Interventions
    Asenapine; Aripiprazole; Quetiapine; Risperidone; Olanzapine; Ziprasidone; Iloperidone; Paliperidone; Lurasidone; Clozapine; Amisulpride; Sertindole; Zotepine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-04-01
    Completion
    2017-12-21
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAsenapine; Aripiprazole; Quetiapine; Risperidone +9 more
    PhaseNot recorded
    Registry statusCompleted

  • The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

    NCT02650102 · start 2013-01

    Registered record
    Registry ID
    NCT02650102
    Conditions
    Schizophrenia
    Interventions
    Risperidone; Olanzapine; Quetiapine; Aripiprazole; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2013-01
    Completion
    2016-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone; Olanzapine; Quetiapine; Aripiprazole +1 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

    NCT01598324 · start 2012-07

    Registered record
    Registry ID
    NCT01598324
    Conditions
    Treatment-Resistant Depression
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2012-07
    Completion
    Not recorded
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment-Resistant Depression
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

    NCT02192723 · start 2012-06

    Registered record
    Registry ID
    NCT02192723
    Conditions
    Schizophrenia
    Interventions
    Typical antipsychotic; Risperidone; Olanzapine; Quetiapine; Aripiprazole; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-06
    Completion
    2014-06
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionTypical antipsychotic; Risperidone; Olanzapine; Quetiapine +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Antipsychotics and Risk of Hyperglycemic Emergencies

    NCT02582736 · start 2012-04

    Registered record
    Registry ID
    NCT02582736
    Conditions
    Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Diabetes Mellitus, Type 2
    Interventions
    Olanzapine; Risperidone; atypical antipsychotics (other); typical antipsychotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-12
    Enrolment
    725,489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder +1 more
    InterventionOlanzapine; Risperidone; atypical antipsychotics (other); typical antipsychotics
    PhaseNot recorded
    Registry statusCompleted

  • The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

    NCT04076371 · start 2012-01

    Registered record
    Registry ID
    NCT04076371
    Conditions
    Schizophrenia
    Interventions
    olanzapine-sertraline combination; only olanzapine; risperidone-sertraline combination; only risperidone; paliperidone-sertraline combination; only paliperidone; ziprasidone-sertraline combination; only ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01
    Completion
    2018-12
    Enrolment
    1,640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionolanzapine-sertraline combination; only olanzapine; risperidone-sertraline combination; only risperidone +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)

    NCT01124877 · start 2010-07

    Registered record
    Registry ID
    NCT01124877
    Conditions
    Bipolar Disorder
    Interventions
    ziprasidone oral capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2010-07
    Completion
    2011-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    Interventionziprasidone oral capsules
    PhasePhase 3
    Registry statusWithdrawn

  • Antipsychotics and Gene Expression in Soft Tissues

    NCT01185743 · start 2010-07

    Registered record
    Registry ID
    NCT01185743
    Conditions
    Schizophrenia; Diabetes
    Interventions
    olanzapine; ziprasidone; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-07
    Completion
    2017-01-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Diabetes
    Interventionolanzapine; ziprasidone; placebo
    PhasePhase 4
    Registry statusCompleted